Seven Fleet Capital Management
Latest statistics and disclosures from Seven Fleet Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CGON, TNGX, RVMD, PHVS, LQDA, and represent 52.90% of Seven Fleet Capital Management's stock portfolio.
- Added to shares of these 10 stocks: CGON (+$129M), TNGX (+$78M), RVMD (+$30M), PHVS (+$21M), MIRM (+$13M), ASMB (+$10M), AVTX (+$10M), ELVN (+$10M), MANE (+$9.8M), ABVX (+$9.1M).
- Started 24 new stock positions in WVE, OKUR, MANE, MIRM, ENGN, RLMD, SGMT, CUE, NGNE, SMMT. AZN, XENE, IHI, OLMA, PRAX, MBX, QURE, STRO, EDIT, ANL, SNDX, STOK, ASND, VKTX.
- Reduced shares in these 10 stocks: Cg Oncology (-$97M), TYRA (-$7.5M), Tango Therapeutics (-$6.3M), AGIO (-$5.7M), Avalo Therapeutics (-$5.4M), Minerva Neurosciences (-$5.4M), PCVX, Pharvaris N V, Soleno Therapeutics, Enliven Therapeutics.
- Sold out of its positions in WHWK, APGE, Ascendis Pharma A S, Avalo Therapeutics, Century Therapeutics, Cg Oncology, CMPS, Compass Therapeutics, CNTX, CGEM.
- Seven Fleet Capital Management was a net buyer of stock by $246M.
- Seven Fleet Capital Management has $602M in assets under management (AUM), dropping by 89.25%.
- Central Index Key (CIK): 0002092021
Tip: Access up to 7 years of quarterly data
Positions held by Seven Fleet Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Seven Fleet Capital Management
Seven Fleet Capital Management holds 96 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cg Oncology (CGON) | 22.3 | $134M | +2389% | 1.9M | 71.05 |
|
| Tango Therapeutics (TNGX) | 15.3 | $92M | +543% | 3.2M | 28.51 |
|
| Revolution Medicines (RVMD) | 7.5 | $45M | +199% | 242k | 187.28 |
|
| Pharvaris N V (PHVS) | 4.4 | $27M | +348% | 775k | 34.58 |
|
| Liquidia Corporation Com New (LQDA) | 3.4 | $21M | +36% | 257k | 79.73 |
|
| Enliven Therapeutics (ELVN) | 3.1 | $19M | +122% | 365k | 50.75 |
|
| Abivax Sa Sponsored Ads (ABVX) | 2.5 | $15M | +158% | 111k | 133.26 |
|
| Avalo Therapeutics Com New (AVTX) | 2.4 | $14M | +260% | 771k | 18.48 |
|
| Mirum Pharmaceuticals (MIRM) | 2.1 | $13M | NEW | 110k | 117.07 |
|
| Assembly Biosciences Com New (ASMB) | 2.0 | $12M | +671% | 433k | 27.48 |
|
| Century Therapeutics (IPSC) | 1.8 | $11M | +47% | 4.3M | 2.45 |
|
| Cytokinetics Com New (CYTK) | 1.7 | $10M | +92% | 118k | 85.19 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 1.7 | $9.9M | +140% | 1.5M | 6.61 |
|
| Veradermics Common Stock (MANE) | 1.6 | $9.8M | NEW | 80k | 122.94 |
|
| Arrivent Biopharma (AVBP) | 1.4 | $8.6M | +390% | 247k | 34.74 |
|
| Tarsus Pharmaceuticals (TARS) | 1.3 | $7.9M | +491% | 117k | 67.57 |
|
| Xencor (XNCR) | 1.3 | $7.8M | +360% | 368k | 21.26 |
|
| Roivant Sciences SHS (ROIV) | 1.3 | $7.8M | +71% | 220k | 35.39 |
|
| Damora Therapeutics Com New (DMRA) | 1.2 | $7.4M | +180% | 284k | 26.01 |
|
| Axsome Therapeutics (AXSM) | 1.2 | $7.1M | +105% | 29k | 244.77 |
|
| Definium Therapeutics Com Shs (DFTX) | 1.2 | $7.0M | +48% | 149k | 47.04 |
|
| Dianthus Therapeutics (DNTH) | 1.0 | $6.3M | +19% | 65k | 97.48 |
|
| Cogent Biosciences (COGT) | 0.9 | $5.7M | 148k | 38.70 |
|
|
| Erasca (ERAS) | 0.9 | $5.6M | +38% | 308k | 18.32 |
|
| Protagonist Therapeutics (PTGX) | 0.9 | $5.6M | +1035% | 45k | 122.58 |
|
| Minerva Neurosciences Com New (NERV) | 0.9 | $5.6M | +303% | 1.0M | 5.55 |
|
| Editas Medicine (EDIT) | 0.7 | $4.3M | NEW | 1.3M | 3.24 |
|
| Cytomx Therapeutics (CTMX) | 0.7 | $4.1M | +192% | 1.1M | 3.75 |
|
| Eupraxia Pharmaceuticals (EPRX) | 0.7 | $4.0M | +40% | 611k | 6.61 |
|
| Sutro Biopharma Com Shs (STRO) | 0.6 | $3.8M | NEW | 159k | 23.85 |
|
| Relay Therapeutics (RLAY) | 0.6 | $3.3M | -30% | 178k | 18.71 |
|
| Celldex Therapeutics Com New (CLDX) | 0.5 | $3.2M | +195% | 87k | 37.21 |
|
| Ascendis Pharma A/s Ord Shs (ASND) | 0.5 | $3.2M | NEW | 12k | 266.72 |
|
| Sagimet Biosciences Com Ser A (SGMT) | 0.5 | $3.1M | NEW | 404k | 7.73 |
|
| Zai Lab Adr (ZLAB) | 0.5 | $2.9M | +74% | 136k | 21.50 |
|
| Sab Biotherapeutics Com New (SABS) | 0.5 | $2.9M | +636% | 736k | 3.90 |
|
| Madrigal Pharmaceuticals (MDGL) | 0.4 | $2.7M | +46% | 5.0k | 536.95 |
|
| Praxis Precision Medicines I Com New (PRAX) | 0.4 | $2.5M | NEW | 7.5k | 334.79 |
|
| Relmada Therapeutics (RLMD) | 0.4 | $2.4M | NEW | 348k | 6.92 |
|
| Agios Pharmaceuticals (AGIO) | 0.4 | $2.1M | -72% | 57k | 37.11 |
|
| Xenon Pharmaceuticals (XENE) | 0.3 | $2.1M | NEW | 33k | 62.60 |
|
| Savara (SVRA) | 0.3 | $1.9M | +4% | 309k | 6.16 |
|
| C4 Therapeutics Com Stk (CCCC) | 0.3 | $1.8M | +567% | 381k | 4.67 |
|
| Vaxcyte (PCVX) | 0.3 | $1.8M | -72% | 30k | 59.65 |
|
| Celcuity (CELC) | 0.3 | $1.7M | +170% | 16k | 104.62 |
|
| Syndax Pharmaceuticals (SNDX) | 0.3 | $1.6M | NEW | 78k | 21.11 |
|
| Zentalis Pharmaceuticals (ZNTL) | 0.2 | $1.5M | +188% | 318k | 4.57 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.2 | $1.4M | +197% | 27k | 53.79 |
|
| Athira Pharma (LONA) | 0.2 | $1.4M | -6% | 154k | 9.19 |
|
| Ideaya Biosciences (IDYA) | 0.2 | $1.4M | -56% | 38k | 37.27 |
|
| Geron Corporation (GERN) | 0.2 | $1.4M | +149% | 1.1M | 1.28 |
|
| Adlai Noryte Sponsored Ads (ANL) | 0.2 | $1.3M | NEW | 113k | 11.50 |
|
| Corvus Pharmaceuticals (CRVS) | 0.2 | $1.2M | 83k | 14.94 |
|
|
| Alkermes SHS (ALKS) | 0.2 | $1.2M | -3% | 23k | 52.40 |
|
| Spyre Therapeutics Com New (SYRE) | 0.2 | $1.2M | -32% | 13k | 88.78 |
|
| Perspective Therapeutics Com New (CATX) | 0.2 | $1.1M | -12% | 333k | 3.41 |
|
| Onkure Therapeutics Com Cl A (OKUR) | 0.2 | $1.1M | NEW | 241k | 4.56 |
|
| Summit Therapeutics (SMMT) | 0.2 | $1.1M | NEW | 73k | 14.88 |
|
| An2 Therapeutics (ANTX) | 0.2 | $1.0M | +4% | 209k | 4.84 |
|
| Contineum Therapeutics Cl A (CTNM) | 0.2 | $992k | +123% | 61k | 16.39 |
|
| Trevi Therapeutics (TRVI) | 0.1 | $833k | +67% | 46k | 18.28 |
|
| Voyager Therapeutics (VYGR) | 0.1 | $772k | +100% | 230k | 3.35 |
|
| Inventiva Sa Ads (IVA) | 0.1 | $757k | 200k | 3.78 |
|
|
| Engene Therapeutics (ENGN) | 0.1 | $711k | NEW | 411k | 1.73 |
|
| Larimar Therapeutics (LRMR) | 0.1 | $704k | -10% | 231k | 3.05 |
|
| Inhibikase Therapeutics Com New (IKT) | 0.1 | $704k | +6% | 347k | 2.03 |
|
| Neurogene (NGNE) | 0.1 | $694k | NEW | 22k | 31.45 |
|
| Ishares Tr U.s. Med Dvc Etf (IHI) | 0.1 | $682k | NEW | 14k | 49.41 |
|
| Silence Therapeutics Ads (SLN) | 0.1 | $660k | -61% | 60k | 10.98 |
|
| Krystal Biotech (KRYS) | 0.1 | $659k | -58% | 1.8k | 371.67 |
|
| Ocuphire Pharma (IRD) | 0.1 | $588k | +6% | 143k | 4.11 |
|
| Palisade Bio (PALI) | 0.1 | $569k | +27% | 272k | 2.09 |
|
| Evolus (EOLS) | 0.1 | $542k | 78k | 6.94 |
|
|
| Unicycive Therapeutics Com New (UNCY) | 0.1 | $521k | +85% | 103k | 5.04 |
|
| Compass Therapeutics (CMPX) | 0.1 | $510k | -54% | 233k | 2.19 |
|
| BioCryst Pharmaceuticals (BCRX) | 0.1 | $510k | -50% | 51k | 10.00 |
|
| Bright Minds Biosciences Com New (DRUG) | 0.1 | $449k | 6.4k | 70.20 |
|
|
| Prothena Corp SHS (PRTA) | 0.1 | $424k | 43k | 9.79 |
|
|
| Monte Rosa Therapeutics (GLUE) | 0.1 | $407k | -25% | 17k | 24.20 |
|
| Olema Pharmaceuticals (OLMA) | 0.1 | $394k | NEW | 32k | 12.51 |
|
| Milestone Pharmaceuticals (MIST) | 0.1 | $362k | -18% | 270k | 1.34 |
|
| Entera Bio SHS (ENTX) | 0.1 | $339k | -6% | 191k | 1.77 |
|
| Cue Biopharma (CUE) | 0.1 | $338k | NEW | 11k | 31.56 |
|
| Mbx Biosciences (MBX) | 0.1 | $331k | NEW | 6.0k | 55.20 |
|
| Beam Therapeutics (BEAM) | 0.1 | $302k | 8.8k | 34.32 |
|
|
| Astrazeneca Ord (AZN) | 0.0 | $266k | NEW | 1.4k | 189.62 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.0 | $261k | -12% | 15k | 17.96 |
|
| Stoke Therapeutics (STOK) | 0.0 | $255k | NEW | 7.7k | 32.97 |
|
| Viking Therapeutics (VKTX) | 0.0 | $252k | NEW | 7.4k | 34.02 |
|
| Lipocine Com New (LPCN) | 0.0 | $202k | -36% | 79k | 2.56 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 0.0 | $201k | -74% | 21k | 9.38 |
|
| Promis Neurosciences Com Shs (PMN) | 0.0 | $140k | 11k | 13.16 |
|
|
| Wave Life Sciences SHS (WVE) | 0.0 | $100k | NEW | 19k | 5.24 |
|
| Pmv Pharmaceuticals (PMVP) | 0.0 | $72k | -15% | 54k | 1.34 |
|
| Fulcrum Therapeutics (FULC) | 0.0 | $66k | -52% | 18k | 3.66 |
|
| Uniqure Nv SHS (QURE) | 0.0 | $15k | NEW | 338.00 | 45.13 |
|
Past Filings by Seven Fleet Capital Management
SEC 13F filings are viewable for Seven Fleet Capital Management going back to 2025
- Seven Fleet Capital Management 2026 Q2 filed Aug. 17, 2026
- Seven Fleet Capital Management 2026 Q1 restated filed June 4, 2026
- Seven Fleet Capital Management 2026 Q1 filed May 15, 2026
- Seven Fleet Capital Management 2025 Q4 restated filed April 2, 2026
- Seven Fleet Capital Management 2025 Q4 filed Feb. 26, 2026